Ezetimibe therapy: mechanism of action and clinical update
Open Access
- 1 July 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Vascular Health and Risk Management
- Vol. 8, 415-427
- https://doi.org/10.2147/VHRM.S33664
Abstract
Peer reviewed article authored by (Phan BAP, Dayspring TD, Toth PP). Read article or submit your manuscript for publishing.Keywords
This publication has 104 references indexed in Scilit:
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemiaVascular Health and Risk Management, 2010
- Statin use and cancer risk: a comprehensive reviewExpert Opinion on Drug Safety, 2010
- Intestinal lipid absorptionAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisThe New England Journal of Medicine, 2009
- Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) TrialJournal of the American College of Cardiology, 2008
- Extracellular loop C of NPC1L1 is important for binding to ezetimibeProceedings of the National Academy of Sciences of the United States of America, 2008
- The Cholesterol Absorption Inhibitor Ezetimibe Acts by Blocking the Sterol-Induced Internalization of NPC1L1Cell Metabolism, 2008
- Hepatic Niemann-Pick C1–like 1 regulates biliary cholesterol concentration and is a target of ezetimibeJCI Insight, 2007
- The seven countries study: 2,289 deaths in 15 yearsPreventive Medicine, 1984